BioMedNewsBreaks

ThursdayJun 18, 2026 1:03 pm

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Positions AI Voice Analysis as Scalable Testing Alternative

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) was featured in a recent TechMediaWire Podcast, where CEO Justin Hanka discussed the company’s plans to commercialize AI-powered voice analysis technology designed to detect alcohol and drug intoxication through non-invasive speech assessment. During the interview, Hanka explained that the company has built prediction models using more than 50 million data points collected through years of clinical research, enabling the identification of intoxication indicators associated with alcohol and drug use. MindBio believes its technology offers a scalable alternative to traditional testing methods that…

Continue Reading

ThursdayJun 18, 2026 12:32 pm

BioMedNewsBreaks — Why Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Is ‘One to Watch’

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. A clinical-stage oncology company , Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is focused on advancing a new class of DNA Damage Response (“DDR”) therapies and developing artificial intelligence-driven precision oncology solutions. “The company is leading the development of Polynucleotide Kinase Phosphatase (‘PNKP’) inhibitors, an emerging category of DDR therapeutics designed to target DNA repair pathways involved in cancer survival and resistance,” reads a recent article. “Through its dual-platform approach, Onco-Innovations combines proprietary drug development with AI-enabled technologies intended to support oncology research, clinical development, patient stratification and evidence generation.” To…

Continue Reading

ThursdayJun 18, 2026 9:42 am

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Reports Proof-of-Concept Data for BiTAC-ADC Cancer Therapy Platform 

VERAXA Biotech (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC(TM)-ADC technology platform, which is designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components. VERAXA said the findings further validate the potential of its BiTAC-ADC platform and complement its BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for…

Continue Reading

ThursdayJun 18, 2026 9:10 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Reports Fiscal 2026 Revenue Growth, Higher Earnings

Earth Science Tech (OTC: ETST) reported financial results for the fiscal year ended March 31, 2026, highlighted by revenue of $35.7 million, up 8% from the prior year, gross profit of $25.5 million, up 5%, and net income of $3.6 million, an 11% increase compared with fiscal 2025. Total assets rose 27% year over year to $9.0 million as the company continued expanding its integrated healthcare platform across telemedicine, pharmacy and fulfillment services. The company also emphasized its capital allocation strategy, noting it repurchased and retired more than 4 million shares during fiscal 2026 and more than 7.1 million shares through…

Continue Reading

ThursdayJun 18, 2026 9:00 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Launches AI-Powered GMP Manufacturing Services Platform at BIO 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform combines the company's PDAOAI™ technology with advanced robotics provided through its collaboration with TechForce Robotics to support pharmaceutical, biotechnology and advanced therapeutics companies seeking to modernize manufacturing operations through AI-driven workflows, digital quality systems and intelligent automation. Oncotelic said the platform is designed to support electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions and process monitoring. The company will also showcase progress with its Deciparticle™ nanomedicine platform, including…

Continue Reading

WednesdayJun 17, 2026 3:30 pm

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Aligns with Growing Shift Toward Predictive, Precision Medicine

Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on personalized, data-driven cardiovascular care powered by artificial intelligence, epigenetics and genetic insights. “Through its proprietary platform and expanding testing capabilities, the company is pursuing a future in which prevention becomes more accessible, scalable and actionable before life-threatening cardiac events occur,” reads a recent article. “The company’s vision reflects a broader shift taking place across the healthcare industry toward predictive and precision medicine. Cardio Diagnostics envisions a healthcare system where every patient receives individualized care informed by their unique molecular insights and where heart disease is no longer the world’s leading killer. Achieving that goal…

Continue Reading

WednesdayJun 17, 2026 11:42 am

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Collaborates with Sysmex to Advance Nu.Q® NETs Assay Development

VolitionRx Limited (NYSE American: VNRX) announced a collaboration with Sysmex (TYO: 6869) to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. The agreement supports Volition's strategy of licensing its proprietary Nu.Q® NETs technology to established global diagnostics companies that can leverage their disease expertise, regulatory capabilities and installed analyzer base to accelerate development and commercialization. Volition said the collaboration has progressed beyond assay transfer and into the optimization phase for diseases associated with NETosis, a process implicated in conditions including sepsis and other acute and chronic diseases. The company believes the Nu.Q® NETs assay could provide improved diagnostic information, support patient monitoring and address a commercial opportunity with an estimated total addressable market of $3.8…

Continue Reading

WednesdayJun 17, 2026 10:33 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Completes AI and Quantum Computing Pilot for PNKP Inhibitor Program 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful completion of a pilot project with Kuano Ltd. that supports advancement of the company's PNKP Inhibitor Technology (ONC010) through AI-enabled and quantum-based computational analysis. Kuano delivered molecular modeling and computational findings that strengthened Onco's understanding of how its PNKP inhibitor and related analogs may interact with the target, producing a refined structural hypothesis for PNKP inhibition and establishing a framework for structure-based optimization and future evaluation. The project also applied quantum-based computational methods to assess PNKP structural behavior and develop human PNKP structural models for follow-on…

Continue Reading

WednesdayJun 17, 2026 9:00 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances AI-Powered GMP Manufacturing Platform

Oncotelic Therapeutics (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing commercialization of an AI-powered good manufacturing practices manufacturing services platform at SAPU Bio, the company's 45%-owned sterile injectable cGMP manufacturing joint venture. The Phase 2 deployment expands the capabilities of Oncotelic's proprietary PDAOAI(TM) platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement. The company said the integrated platform combines PDAOAI(TM) with TechForce's autonomous robotic systems to support intelligent pharmaceutical manufacturing and create potential opportunities in software licensing, automation deployment, manufacturing partnerships…

Continue Reading

TuesdayJun 16, 2026 1:57 pm

BioMedNewsBreaks — Humacyte Inc. (NASDAQ: HUMA) Prices $50 Million Public Offering 

Humacyte (NASDAQ: HUMA) announced the pricing of an underwritten public offering of 47.6 million shares of common stock at $1.05 per share, with expected gross proceeds of approximately $50 million before underwriting discounts, commissions and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 7.1 million shares at the public offering price. The offering is expected to close on or about June 12, 2026, subject to customary closing conditions. Humacyte said it intends to use the net proceeds to support commercialization of Symvess(R), advance a planned Biologics License Application supplement filing for a hemodialysis indication, fund development of pipeline candidates and provide working capital…

Continue Reading